Eye Insitute, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates (UAE).
Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, Cleveland, Ohio, USA.
Ocul Immunol Inflamm. 2021 Aug 18;29(6):1132-1136. doi: 10.1080/09273948.2020.1727530. Epub 2020 Apr 7.
: To compare immediate versus delayed introduction of immunosuppressives for naive noninfectious inflammatory choroidal neovascularization (iCNV).: a retrospective, consecutive, comparative, interventional case series of patients with a diagnosis of inflammatory CNV and a minimum follow of 36 months. Patients were divided into two groups: Group A received Immunosuppressives if needed, while Group B since baseline. Both groups received systemic steroids and intravitreal ranibizumab since baseline. Primary end point was to compare the BCVA outcome till 36-month follow-up.: Twenty-nine eyes with iCNV were enrolled. In the long term, best-corrected visual acuity (BCVA) was significantly better in group B. At 3-month follow-up, Group B reduced steroids <10 mg/day significantly ( = .0001, Fisher's Exact Test). At 36 months of follow up, injections given were 2.9 (0.9 SD) in group A and 1.25 (0.4 SD) in group B.: early immunosuppressive therapy exerts a positive action on the long-term control of uveitic CNV.
比较初发非感染性炎症性脉络膜新生血管（iCNV）患者即刻与延迟使用免疫抑制剂治疗：一项回顾性、连续、对照、干预性病例系列研究，纳入了诊断为炎症性 CNV 且随访至少 36 个月的患者。患者分为两组：A 组根据需要使用免疫抑制剂，B 组从基线开始使用。两组均从基线开始接受全身皮质类固醇和玻璃体内雷珠单抗治疗。主要终点是比较 36 个月随访时的最佳矫正视力（BCVA）结果。共纳入 29 只眼的 iCNV。长期来看，B 组的最佳矫正视力（BCVA）明显更好。在 3 个月随访时，B 组显著减少了 <10 mg/天的皮质类固醇（=0.0001，Fisher 确切检验）。在 36 个月的随访时，A 组的注射次数为 2.9（0.9 SD），B 组为 1.25（0.4 SD）。早期免疫抑制治疗对葡萄膜炎性脉络膜新生血管的长期控制有积极作用。
